AlphaQuest LLC Has $706,000 Holdings in Supernus Pharmaceuticals, Inc. $SUPN

AlphaQuest LLC lifted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 360.0% during the 2nd quarter, Holdings Channel reports. The fund owned 22,391 shares of the specialty pharmaceutical company’s stock after acquiring an additional 17,523 shares during the quarter. AlphaQuest LLC’s holdings in Supernus Pharmaceuticals were worth $706,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter worth approximately $1,536,000. Mutual of America Capital Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 5.3% in the 2nd quarter. Mutual of America Capital Management LLC now owns 212,691 shares of the specialty pharmaceutical company’s stock worth $6,704,000 after acquiring an additional 10,726 shares in the last quarter. Yousif Capital Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 1.5% in the 2nd quarter. Yousif Capital Management LLC now owns 21,032 shares of the specialty pharmaceutical company’s stock worth $663,000 after acquiring an additional 305 shares in the last quarter. Meritage Portfolio Management boosted its holdings in shares of Supernus Pharmaceuticals by 2.7% in the 2nd quarter. Meritage Portfolio Management now owns 60,398 shares of the specialty pharmaceutical company’s stock worth $1,904,000 after acquiring an additional 1,595 shares in the last quarter. Finally, CWM LLC boosted its holdings in shares of Supernus Pharmaceuticals by 92.4% in the 2nd quarter. CWM LLC now owns 3,080 shares of the specialty pharmaceutical company’s stock worth $97,000 after acquiring an additional 1,479 shares in the last quarter.

Analysts Set New Price Targets

SUPN has been the subject of several research analyst reports. Piper Sandler upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $40.00 to $65.00 in a research report on Thursday, October 9th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 17th. TD Cowen boosted their price objective on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $62.67.

Supernus Pharmaceuticals Stock Down 0.2%

SUPN opened at $52.72 on Tuesday. Supernus Pharmaceuticals, Inc. has a 12 month low of $29.16 and a 12 month high of $54.79. The company has a fifty day simple moving average of $47.07 and a 200 day simple moving average of $38.16. The stock has a market cap of $2.96 billion, a P/E ratio of 45.84 and a beta of 0.78.

Insider Activity at Supernus Pharmaceuticals

In related news, SVP Frank Mottola sold 14,000 shares of the company’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $44.51, for a total value of $623,140.00. Following the completion of the transaction, the senior vice president directly owned 15,496 shares of the company’s stock, valued at approximately $689,726.96. This represents a 47.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jack A. Khattar sold 140,000 shares of the company’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $42.02, for a total transaction of $5,882,800.00. Following the completion of the transaction, the chief executive officer directly owned 1,030,183 shares of the company’s stock, valued at approximately $43,288,289.66. The trade was a 11.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 362,741 shares of company stock valued at $16,390,592 in the last quarter. 8.80% of the stock is currently owned by company insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.